{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-122156","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2025-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.402507+00:00","generated_at":"2026-05-21T02:11:21.087654+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Prime Medicine CEO Gottesdiener resigns; Reine named CEO; positive CGD data; restructures to liver focus","bullets":["Keith Gottesdiener resigned as CEO and board member; CFO Allan Reine appointed CEO and to board, effective May 19, 2025.","Jeff Marrazzo named Executive Chair of the board.","First clinical data for PM359 in CGD: 58% DHR positivity at Day15, 66% at Day30, well above 20% threshold; rapid engraftment.","Company to deprioritize CGD programs, seek partner for PM359; focus on Wilson's Disease and AATD with IND/CTA in 1H2026 and mid-2026.","Workforce reduction and cost cutting to reduce cash needs; Beam arbitration ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-122156","json":"https://secwatch.observer/filing/0001193125-25-122156.json","markdown":"https://secwatch.observer/filing/0001193125-25-122156.md","text":"https://secwatch.observer/filing/0001193125-25-122156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000119312525122156/0001193125-25-122156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000119312525122156/d863812d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T02:11:21.087654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2eca06f1a1","claim":"Allan Reine was appointed as member of the Board of Directors at Prime Medicine, Inc..","evidence_excerpt":"The Board also appointed Dr. Reine to serve as a member of the Board as a Class II director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1894562/000119312525122156/0001193125-25-122156-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"70a844909c","claim":"Keith Gottesdiener resigned as President, Chief Executive Officer and principal executive officer at Prime Medicine, Inc..","evidence_excerpt":"Keith Gottesdiener, M.D. had resigned as President, Chief Executive Officer and principal executive officer of the Company, and as a member of the Board of Directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1894562/000119312525122156/0001193125-25-122156-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President, Chief Executive Officer and principal executive officer"}],"fact_type":"executive_change"},{"claim_id":"8114b9edde","claim":"Allan Reine was appointed as Chief Executive Officer and principal executive officer at Prime Medicine, Inc..","evidence_excerpt":"the Board appointed Allan Reine, M.D., the Company’s Chief Financial Officer and principal financial officer, as Chief Executive Officer and principal executive officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1894562/000119312525122156/0001193125-25-122156-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer and principal executive officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}